[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562913":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":51,"collaborators":20,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":20,"studyType":68,"phases":69,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":79,"whyStopped":20,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"The University of Texas Health Science Center at San Antonio","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Hemodialysis Group","EXPERIMENTAL","Fixed dose bupropion hydrochloride 150 mg extended-release tablets will be administered orally thrice a week during routine dialysis sessions for consecutive 8 weeks.",[13],"Drug: Bupropion Hydrochloride 150 MG",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Bupropion Hydrochloride 150 MG","Bupropion Hydrochloride Extended Release is administered orally three times a week during routine dialysis sessions for 8 consecutive weeks",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Subrata Debnath, MB.BS, Ph.D.","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Subrata Debnath, MB.BS, PhD","CONTACT","210-567-4700","nath@uthscsa.edu",{"name":32,"role":28,"phone":29,"phoneExt":20,"email":33},"Swetha Kanduri, MD","kanduri@uthscsa.edu",[35],{"facility":36,"status":20,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"University Hospital Dialysis Medical Center (DMC)","San Antonio","Texas","78229","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-98.49363,29.42412,{"lat":46,"lon":45},[49],{"name":50,"role":28,"phone":29,"phoneExt":20,"email":30},"Subrata Debnath, PhD",{"type":24,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Subrata Debnath","Assistant Professor","100562913","phase-1-bupropion-for-fatigue-in-end-stage-kidney-disease-patients-on-hemodialysis-100562913",false,"NCT06609343","Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis","Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis (BRISK)","BRISK","Inclusion Criteria:\n\n1. Male and female ESKD patients between aged 25-74 yrs on maintenance in-center hemodialysis procedure 3 times\u002Fweek for ≥3 months with an arteriovenous fistula or graft.\n2. Blood hemoglobin of ≥10.0 g\u002FdL based on most recent routine laboratory profile.\n3. Dialysis adequacy measured with Kt\u002FV of ≥1.2\n4. Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n1. Currently on bupropion or hypersensitivity\u002F intolerance to bupropion by history and monoamine oxidase inhibitors.\n2. Diagnosis or history of eating disorders (bulimia or anorexia nervosa) and seizure.\n3. Pregnant, lactating, childbearing women\n4. History of post-acute COVID-19 syndrome\n5. Diagnosis of depression and\u002For on antidepressants and bipolar affective disorder\n6. Patient Health Questionnaire (PHQ)-9 score of ≥10\n7. Diagnosis of cognitive impairment including dementia\n8. Current participation in another interventional trial\n9. Scheduled for kidney transplantation in next 6 months\n10. Life expectancy \\\u003C6 months as judged by the attending nephrologist\u002Fprimary care physician.\n11. Current or history of substance abuse or dependency.","ALL","25 Years","74 Years",{"count":66,"type":67},16,"ESTIMATED","INTERVENTIONAL",[70,71],"PHASE1","PHASE2","Fatigue is the most common symptom reported by end-stage kidney disease patients on maintenance hemodialysis. Unfortunately, there currently is no medical management for this overwhelming feeling of tiredness. As a result, patients continue to suffer with poor quality of life and impaired daily activities. The purpose of this pilot trial is to find out if bupropion (a medicine commonly prescribed for stopping smoking, seasonal mood disorder, and depression) may help lessen fatigue in hemodialysis patients.\n\nIn this study, hemodialysis participants will receive bupropion tablet orally three times a week during routine dialysis procedure for consecutive 8 weeks. Study participants will complete a battery of questionnaires to self-report fatigue, cognition, and quality of life. The study team will collect biological specimens. All these procedures will be performed at the dialysis clinic during routine dialysis procedure.",[74,75],"End Stage Renal Disease","Fatigue",[77,78],"Hemodialysis","Kidney dialysis","NOT_YET_RECRUITING","2026-03-10",{"date":82,"type":83},"2026-03-12","ACTUAL",{"date":85,"type":67},"2026-06-01",{"date":87,"type":67},"2027-01-30",{"name":5,"class":6},1]